29.08.2006 11:00:00

DexCom Receives FDA Approval for DM(TM) Consumer Data Manager; Software for Patients to Download Data From STS(TM) Continuous Glucose Monitoring System

DexCom, Inc. (NASDAQ: DXCM) announced today that it hasreceived approval from the Food and Drug Administration (FDA) for itsDM(TM) Consumer Data Manager, a software program that allows peoplewith diabetes to download the data from their DexCom STS(TM)Continuous Glucose Monitoring Systems onto their personal computers.The software enables patients to download and view up to 30 days ofhistorical glucose trends and patterns.

"We are very pleased to begin providing the DexCom DM ConsumerData Manager, as this was one of top requests from our customers foradditional features for the STS Continuous Glucose Monitoring System.The software was designed to be easy to use and we are hopeful thesoftware will help patients gain better insight into their diabetes,"said Tae Andrews, DexCom's Vice President of Marketing. "We arecommitted to providing leadership in the continuous glucose monitoringcategory and to continued improvement of our STS platform. Since thelaunch of our STS Continuous Glucose Monitoring System in March 2006,we have introduced Health Care Professional Patient Manager softwareand filed a PMA-Supplement with the FDA for our second generation7-day STS Continuous Glucose Monitoring System."

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, isdeveloping and marketing continuous glucose monitoring systems forpeople with diabetes.

Cautionary Statement Regarding Forward Looking Statements

DexCom is a medical device company with a limited operatinghistory. The company received approval from the FDA for its STScontinuous glucose monitor on March 24, 2006, and has only recentlylaunched the sale of this product throughout the United States.Successful commercialization of the company's products is subject tonumerous risks and uncertainties, including a lack of acceptance inthe marketplace by physicians and patients, the inability tomanufacture products in commercial quantities at an acceptable cost,possible delays in the company's development programs, the inabilityof patients to receive reimbursements from third-party payors andinadequate financial and other resources. Certain of these risks anduncertainties, in addition to other risks, are more fully described inthe company's quarterly report on Form 10-Q for the period ending June30, 2006, as filed with the Securities and Exchange Commission on July21, 2006.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu DexCom Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

DexCom Inc. 76,00 -1,69% DexCom Inc.

Indizes in diesem Artikel

NASDAQ Comp. 19 161,63 -1,63%